Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nuvastatic · 1 trial · 1 indication
Central Subfield Retinal Thickness
protein biomarkers
Visual Acuity Letter Score
| Arm | Type | Description |
|---|---|---|
| NuvastaticTM 1000 mg | EXPERIMENTAL | NuvastaticTM 1000 mg(standardized extract of Orthosiphon Stamineus) will be given orally, three times per day for 12 months. |
| Placebo | ACTIVE_COMPARATOR | NuvastaticTM (without active) will be given orally, three times per day for 12 months |
| Name | Type | Description |
|---|---|---|
| Nuvastatic | DRUG | Phase 1b Interventional, multi-centered, double-masked, randomized |
| Placebo | OTHER | Phase 1b Interventional, multi-centered, double-masked, randomized |
Inclusion Criteria: * • Type-2 Diabetes mellius (NIDDM) patients of both genders aged 18-65 years. * Able and willing to provide written informed consent. * Documented diagnosis of Type 2 diabetes mellitus a glycosylated hemoglobin A1c (HbA1c) of ≤ 12.0% at screening. * Patients preferably o...
Nuvastatic is an investigational small molecule being developed for diabetic retinopathy, a complication of diabetes that damages blood vessels in the retina. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. One clinical trial has been completed to evaluate its efficacy and safety in this condition.
Nuvastatic is being developed by Quest Diagnostics Inc., a company publicly traded under the ticker symbol DGX. The drug is an investigational small molecule intended for the treatment of diabetic retinopathy. It is currently in Phase 1 clinical development, with one completed trial.
Nuvastatic is in Phase 1 clinical development. It is an investigational small molecule for diabetic retinopathy and has not yet been approved by regulatory authorities. One Phase 1 trial has been completed, involving 100 participants, and the drug remains under investigation.
Nuvastatic has been studied in one clinical trial, identified as NCT04552600, titled "Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy." This Phase 1 trial was completed in India, enrolled 100 participants aged 18 years and older, and used an active-controlled design.
Yes, Nuvastatic is also known as C5OSEW5050ESA. The clinical trial NCT04552600, which evaluated the drug in diabetic retinopathy, refers to it as "Nuvastatic™ - C5OSEW5050ESA," confirming that these names refer to the same investigational small molecule.